MentionFox
Home › funding signals › Tempest Therapeutics, Inc.
Form D · on the record

Tempest Therapeutics — $7.50M Form D filing, October 2026

Tempest Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-14.

Sell to companies like these? Paste your website and see 10 with a filed reason to buy this month. Free.

Opens in a new tab. No signup.

Run the free check on Tempest Therapeutics, Inc. →

Tempest Therapeutics, Inc.

New Form D on file · 2026-10-14 · the record

$7.50M
raise on the record
D
filing
1
investors in
CALIFORNIA
based
Open the record →

What the record says

FilingForm D
Filed2026-10-14
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedBRISBANE, CALIFORNIA
CIK1544227
Accession0001213900-26-109190

Pitching, partnering or investing alongside them? See who really runs and owns Tempest Therapeutics, Inc.

Watch Tempest Therapeutics, Inc.

Free to see. No signup.

What do you want to do with Tempest Therapeutics, Inc.?

Get the full cited report on Tempest Therapeutics, Inc.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Tempest Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Full funding history for Tempest Therapeutics, Inc. →

Key facts

  • · Form D filed with the SEC · Form D
  • · Sold to date: $7.50M · Form D
  • · Total offering: $7.50M · Form D
  • · First sale: 2026-09-15 · Form D
  • · Investors already in: 1 · Form D

What the filing says

  • Offered: $7,500,000. Sold: $7,500,000. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 1 had already invested. (filing)
  • Date of first sale: September 15, 2026. (filing)
  • Types of securities: Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right; Other: Pre-funded warrants and Series C and Series D Common Stock Purchase Warrants, including underlying shares of common stock.. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)
  • On the amounts offered and sold: the filing adds “Offering of 3,105,591 pre-funded warrants and accompanying 3,105,591 Series C and 3,105,591 Series D warrants, including the common stock underlying such warrants at combined exercise price of $0.804. Total offering amount excludes PA warrants (Item 15).” (filing)
  • On sales commissions and finders' fees: the filing adds “Includes a cash placement fee equal to 7.0% of the gross proceeds of the offering, reimbursement of $50,000 legal fees and warrants, exercisable upon stockholder approval, to purchase 217,391 common stock at an exercise price of $1.0063 per share.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Tempest Therapeutics, Inc. See pricing

Filing history · 3 filings on this registrant
Form D · 2026-04-03 · $2MForm D · 2026-06-23 · $4.06MForm D · 2026-10-14 · $7.50M · this page 2026-04-03 2026-10-14

Each marker is one filing. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $7.50M, filed week of Oct 12

Trailing twelve months. 774 filings in Biotechnology, totalled by week. The dot is this raise, $7.50M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Tempest Therapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Tempest Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Tempest Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on Target: the verdict, 16 sections, 39 cited sources, dated 2026-09-28A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Tempest Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Tempest Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

More on Tempest Therapeutics, Inc.

Share this page

Just raised? Share it.

Tempest Therapeutics, Inc.: Raised $7.50M, Form D filed 2026-10-14
Download image Share on LinkedIn Share on X

Cite this page

Permanent URL: https://mentionfox.com/funding/tempest-therapeutics-inc-form-d-109190
Last updated 2026-10-16
Primary record: SEC filing 1 · SEC filing 2
Tempest Therapeutics raised $7.50M — SEC Form D filing, October 2026. MentionFox, 2026-10-16. https://mentionfox.com/funding/tempest-therapeutics-inc-form-d-109190